Inventiva S.A.
IVEVF
Other OTC4.00
USD
-1.33
- -
CIK
0001756594
ISIN
FR0013233012
Return %
Stock
S&P500
1Y
75.44
26.53
3Y
1.27
76.60
5Y
-63.10
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Andrew Obenshain
- Full Time Employees
- 114
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 50 rue de Dijon Daix France 21121
- IPO Date
- May 7, 2019
- CIK
- 0001756594
- Website
- inventivapharma.com
- Similar Companies
- Business
- Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for patients with significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. Founded in 2011 and headquartered in Daix, France, the company advances a pipeline backed by a proprietary discovery engine featuring an extensive library of approximately 240,000 pharmacologically relevant molecules, a wholly-owned research and development facility, and expertise in compounds targeting nuclear receptors, transcription factors, and epigenetic modulation. Its lead product candidate, lanifibranor, a pan-peroxisome proliferator-activated receptor (PPAR) agonist, is in a pivotal Phase III NATiV3 clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), addressing steatosis, inflammation, ballooning, and fibrosis; lanifibranor previously demonstrated statistically significant efficacy in Phase IIb for NASH resolution without fibrosis worsening, fibrosis improvement without NASH worsening, and composite endpoints, earning FDA Breakthrough Therapy Designation. The pipeline also includes odiparcil, an orally available small molecule for mucopolysaccharidoses (MPS) types including MPS VI, designed to promote excretion of glycosaminoglycans to reduce cellular accumulation, though clinical efforts on odiparcil are suspended to prioritize lanifibranor while options for further development are reviewed; earlier-stage programs target the Hippo signaling pathway in oncology and other preclinical assets in fibrosis and rare diseases. Inventiva maintains licensing and collaboration agreements with partners including Sino Biopharm, Hepalys Pharma, Inc., Chia Tai Tianqing Pharmaceutical (CTTQ), AbbVie, and Boehringer Ingelheim, supporting revenue from research partnerships primarily in France. Recent developments include the completion in December 2024 of the first tranche of a multi-tranche equity financing announced in October 2024, securing €116 million including a €21.4 million issuance following shareholder approval, with potential for up to €348 million total to fund NATiV3 advancement and potential new drug application submission; recruitment for NATiV3 is intensifying with completion expected in the first half of 2025; governance changes feature the appointment of Mark Pruzanski as Chairman of the Board and Srinivas Akkaraju as a director, alongside separation of CEO and Chairman roles with Frédéric Cren as CEO; and receipt of a $10 million milestone from CTTQ under an amended licensing agreement. The company trades on Euronext Paris (IVA) and Nasdaq Global Market (IVA) with a scientific team of approximately 90 people.